Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.52 |
| ▸ | LMNA | P02545 | 4/20 | 0.52 |
| ▸ | MAPT | P10636 | 4/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.52 |
| ▸ | HPGD | P15428 | 2/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.52 |
| ▸ | NPC1 | O15118 | 1/20 | 0.52 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.52 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.52 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.52 |
| ▸ | RAB9A | P51151 | 1/20 | 0.52 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.52 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.52 |
| ▸ | PPARD | Q03181 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.46 |
| ▸ | TSHR | P16473 | 3/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL406835 | 0.84 | CYP1A2 (0.56) | ALDH1A1L3MBTL1TDP1LMNAMAPT | |
| SCHEMBL365813 | 0.81 | ELANE (0.54) | ALDH1A1L3MBTL1TDP1LMNASMN1; SMN2 | |
| SCHEMBL21381324 | 0.80 | TDP1 (0.57) | ALDH1A1L3MBTL1TDP1MAPTSMN1; SMN2 | |
| Dimethylamine SCHEMBL4372531 | 0.79 | CYP1A2 (0.51) | ALDH1A1L3MBTL1TDP1LMNAMAPT | |
| SCHEMBL924662 | 0.79 | CYP1A2 (0.50) | ALDH1A1L3MBTL1LMNAMAPTSMN1; SMN2 | |
| SCHEMBL11783230 | 0.79 | PTGDR2 (0.60) | USP2ALDH1A1L3MBTL1TDP1LMNA | |
| SCHEMBL20213835 | 0.78 | KMT2A (0.57) | ALDH1A1L3MBTL1TDP1LMNAMAPT | |
| SCHEMBL7540395 | 0.78 | KMT2A (0.51) | ALDH1A1L3MBTL1LMNAMAPTSMN1; SMN2 | |
| SCHEMBL5562266 | 0.78 | KMT2A (0.51) | ALDH1A1L3MBTL1LMNAMAPTSMN1; SMN2 | |
| SCHEMBL2097272 | 0.78 | KMT2A (0.51) | ALDH1A1L3MBTL1LMNAMAPTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3253735-B1 | LATENT ACIDS AND THEIR USE | BASF SE (DE) | 2021-03-31 | — | — | EP | disclosed |
| US-20180009775-A1 | LATENT ACIDS AND THEIR USE | BASF SE (DE) | 2018-01-11 | — | — | US | disclosed |
| WO-2016124493-A1 | LATENT ACIDS AND THEIR USE | BASF SE (DE) | 2016-08-11 | — | — | WO | disclosed |
| US-20110171569-A1 | SULFONIUM DERIVATIVES AND THE USE THEROF AS LATENT ACIDS | BASF SE (DE) | 2011-07-14 | — | — | US | disclosed |
| EP-1020445-B1 | FUSED PYRIDINE DERIVATIVES | EISAI R&D MAN CO LTD (JP) | 2008-08-13 | — | — | EP | disclosed |
| EP-1769286-A2 | OXIME DERIVATIVES AND THE USE THEROF AS LATENT ACIDS | Ciba Specialty Chemicals Holding Inc. (CH) | 2007-04-04 | — | — | EP | disclosed |
| WO-2006008250-A2 | OXIME DERIVATIVES AND THE USE THEROF AS LATENT ACIDS | CIBA SPECIALTY CHEMICALS HOLDING INC. (CH) | 2006-01-26 | — | — | WO | disclosed |
| US-6875761-B2 | Certain 1,3-disubstituted isoquinoline derivatives | EISAI CO., LTD. (JP) | 2005-04-05 | — | — | US | disclosed |
| US-20040204421-A1 | Certain 1,3-disubstituted isoquinoline derivatives | EISAI CO., LTD. | 2004-10-14 | — | — | US | disclosed |
| US-6790844-B2 | MUSCLE RELAXANTS; ANTISEROTONINE AGENT | EISAI CO., LTD (JP) | 2004-09-14 | — | — | US | disclosed |
| US-20020013460-A1 | Condensed pyridine compound | EISAI CO., LTD | 2002-01-31 | — | — | US | disclosed |
| US-6340759-B1 | ANTISPASMODIC AGENTS | EISAI CO., LTD. (JP) | 2002-01-22 | — | — | US | disclosed |
| EP-1020445-A1 | FUSED PYRIDINE DERIVATIVES | Eisai Co., Ltd. (JP) | 2000-07-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180009775-A1 | LATENT ACIDS AND THEIR USE | LTA, C1S, C9 | USP2 3388/4885ALDH1A1 217/4885L3MBTL1 187/4885 |
| US-20020013460-A1 | Condensed pyridine compound | MUSK, HTR1A, PAX3 | USP2 3459/4885ALDH1A1 2989/4885L3MBTL1 4124/4885 |
| US-20040204421-A1 | Certain 1,3-disubstituted isoquinoline derivatives | MUSK, HTR1A, RYR1 | USP2 2242/4885ALDH1A1 1071/4885L3MBTL1 2776/4885 |
| US-20110171569-A1 | SULFONIUM DERIVATIVES AND THE USE THEROF AS LATENT ACIDS | NR2E3, HCAR3, HRH4 | USP2 2924/4885ALDH1A1 1482/4885L3MBTL1 206/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.